ARIAD to Present Data on Pan-BCR-ABL Inhibitor AP24534 at 51st American Society of Hematology Meeting
Clinical Proof-of-Concept Data to be Presented December 7, 2009
ARIAD to Hold Conference Call to Discuss Findings December 8, 2009
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Nov 23, 2009 - ARIAD Pharmaceuticals, Inc. (NASDAQ: ARIA) today announced that the Company and collaborating investigators from five major oncology research centers in the United States will present data from a Phase 1 clinical trial of ARIAD's investigational, multi-targeted kinase inhibitor and pan-BCR-ABL inhibitor, AP24534, at the 51st Annual Meeting of the American Society of Hematology (ASH) being held in New Orleans, Louisiana, December 5-8, 2009. The Phase 1 clinical proof-of-concept data on AP24534 in patients with resistant and refractory chronic myeloid leukemia (CML) will be presented by Jorge Cortes, M.D., Professor and Deputy Chair, Department of Leukemia at the M.D. Anderson Cancer Center.
ARIAD announced preliminary trial results on AP24534 earlier this year, outlining initial clinical evidence of hematologic, cytogenetic and molecular responses and anti-cancer activity of AP24534 in heavily pretreated patients with resistant and refractory CML and Philadelphia-positive acute lymphoblastic leukemia, including those with the T315I mutant variant of the target protein, BCR-ABL.
In addition to M.D. Anderson, other clinical research sites participating in this study of AP24534 include the Oregon Health and Science University, the University of California at San Francisco, Sarah Cannon Research Institute and the University of Michigan Medical School.
The schedule and meeting place for the session, together with the abstract information, are listed below:
“A Phase 1 Trial of Oral AP24534 in Patients with Refractory
Chronic Myeloid Leukemia and Other Hematologic Malignancies: First
Results of Safety and Clinical Activity against T315I and Resistant
|Presenter:||Jorge Cortes, M.D. (M.D. Anderson Cancer Center)|
|Oral Session:||Chronic Myeloid Leukemia - Therapy: Managing Resistance and Residual Disease|
|Date/Time:||Monday, December 7, 2009 at 4:30 p.m. (CT)/5:30 p.m. (ET)|
|Location:||Ernest N. Morial Convention Center, Auditorium AB|
ARIAD's vision is to transform the lives of cancer patients with breakthrough medicines. The Company's mission is to discover, develop and commercialize small-molecule drugs to treat cancer in patients with the greatest and most urgent unmet medical need – aggressive cancers where current therapies are inadequate. ARIAD's lead product candidate, ridaforolimus, is an investigational mTOR inhibitor in Phase 3 clinical development in patients with advanced sarcomas and is being developed in collaboration with Merck & Co., Inc. ARIAD's second product candidate, AP24534, is an investigational multi-targeted kinase inhibitor in Phase 1 clinical development in patients with hematological cancers. ARIAD has an exclusive license to pioneering technology and patents related to certain NF-ÎºB cell-signaling activity, which may be useful in treating certain diseases. For additional information about the Company, please visit http://www.ariad.com.
ARIAD Pharmaceuticals, Inc.
Maria E. Cantor, 617-621-2208
Posted: November 2009